Written by According to Fortune Business Insights, the global gene therapy market was valued at USD 3.57 billion in 2025 and is projected to grow from USD 4.22 billion in 2026 to USD 20.68 billion by 2034, registering a CAGR of 21.97% during the forecast period from 2026 to 2034. North America dominated the market, accounting for a 65.83% share in 2025.
Market Overview
Gene therapy represents an important area of advanced medical treatment because it is designed to address the underlying genetic causes of disease. Growing demand for therapies capable of treating genetic disorders and rare diseases is contributing to the expansion of the market.
The industry is also benefiting from increased investment in research and development, product launches, regulatory approvals, and funding for innovative technologies. For example, SpliceBio received USD 127.7 million in Series B funding in June 2025 to advance gene therapy. Such investments demonstrate the increasing focus on developing innovative treatment approaches and expanding the gene therapy pipeline.
For detailed market insights: https://www.fortunebusinessinsights.com/industry-reports/gene-therapy-market-100243
Market Trends
Increasing Focus on Manufacturing Scalability
Improving manufacturing scalability is one of the prominent trends shaping the gene therapy market. Growing demand for viral vectors and an expanding number of clinical candidates are encouraging companies to increase manufacturing capabilities.
Companies are integrating next-generation bioprocessing technologies, automated systems, and modular facilities to achieve higher yields and consistent product quality. In October 2024, the Cell and Gene Therapy Catapult partnered with Pharmaron Biologics (UK) Ltd and Complement Therapeutics and received a USD 1.5 million grant under the U.K. Transforming Medicines Manufacturing Programme. The initiative aimed to reduce AAV production costs and improve scalability.
Advancements in Gene Delivery Systems
Innovation in gene delivery is another important development. New delivery systems are being developed to improve tissue specificity, reduce immune activation, and simplify large-scale production. In May 2025, Dyno Therapeutics launched three new AAV capsid gene delivery vectors targeting the eye, musculoskeletal system, and central nervous system.
Market Drivers
Rising Burden of Genetic Disorders
The increasing prevalence of genetic disorders is a major factor driving gene therapy market growth. Conditions such as spinal muscular atrophy, hemophilia, β-thalassemia, and inherited retinal diseases are increasing demand for treatments that can address the root cause of disease.
The World Federation of Hemophilia reported 218,804 patients with hemophilia in 2023, highlighting the need for effective therapeutic options. Increasing demand for curative treatments is expected to strengthen the adoption of gene therapies.
Growing R&D and Regulatory Support
Advances in gene therapy technologies, greater research activity, funding opportunities, product launches, and regulatory approvals are also contributing to market expansion. Strong investments by biotechnology and pharmaceutical companies are helping develop new therapies and broaden the availability of treatment options.
Market Restraints and Challenges
Despite strong growth prospects, the high cost of gene therapies remains a significant barrier to patient access. The substantial financial burden affects patients, payers, and healthcare systems. For example, the first gene therapy for hemophilia B approved by the U.S. FDA in December 2022 carried a one-time treatment cost of USD 3.5 million.
Maintaining clinical efficiency over the long term is another challenge. Transgene expression may decline because of immune responses, promoter silencing, or loss of modified cells, making long-term monitoring and follow-up necessary.
Market Segmentation
By Product
Based on product, the market is segmented into Zolgensma, Luxturna, Roctavian, and others. Zolgensma dominated the product segment in 2025, with an estimated value of USD 1.23 billion. Its established durability and use in treating spinal muscular atrophy support its leading position. The others segment is projected to grow at a CAGR of 22.70% during the forecast period.
By Vector Type
The market is divided into viral vectors and non-viral vectors. Viral vectors accounted for a dominant 98.6% share in 2025, supported by their high transduction efficiency, targeted genetic material delivery, and long-lasting expression. Meanwhile, the non-viral vector segment is expected to grow at a strong 45.91% CAGR over the forecast period.
By Indication
By indication, the market includes genetic disorders, ophthalmology, hematology, and others. Genetic disorders held the leading position with a 65.5% share in 2025, reflecting the growing demand for curative and personalized treatments. The ophthalmology segment is expected to register a 39.89% CAGR during the forecast period.
By End User
The end-user segmentation comprises hospitals & clinics, specialty clinics, and others. Hospitals & clinics dominated in 2025 with a 53.38% share, supported by their role in clinical trials, treatment delivery, monitoring, and oversight. The specialty clinics segment is projected to grow at a 23.69% CAGR during the study period.
Key Players
The gene therapy market has a semi-concentrated competitive structure, with established companies and small- to mid-sized players competing through product innovation, R&D, strategic partnerships, and geographical expansion.
Major companies include Novartis AG, F. Hoffmann-La Roche Ltd., BioMarin Pharmaceutical Inc., CSL, Vertex Pharmaceuticals Incorporated, Krystal Biotech, Inc., Rocket Pharmaceuticals, and Dyno Therapeutics, Inc. Novartis AG and F. Hoffmann-La Roche Ltd. maintain strong positions through broad product portfolios, innovative launches, geographic expansion, and strategic initiatives.
Regional Analysis
North America
North America was the leading regional market, valued at USD 2.35 billion in 2025 and accounting for a 65.83% market share. Growth is supported by strong R&D activity, advanced healthcare infrastructure, rapid FDA approvals, leading biotechnology and pharmaceutical companies, and substantial venture capital and government funding. The U.S. market reached USD 2.19 billion in 2025.
Europe
Europe was valued at USD 1.07 billion in 2025 and is projected to grow at a 20.64% CAGR during the forecast period. Supportive regulatory pathways, research collaborations, and reimbursement initiatives are among the factors supporting regional growth. Germany, the U.K., and France recorded estimated market values of USD 0.26 billion, USD 0.17 billion, and USD 0.18 billion, respectively, in 2025.
Asia Pacific
Asia Pacific reached an estimated USD 0.06 billion in 2025, supported by expanding healthcare infrastructure and research activities. China and India were estimated at USD 0.02 billion and USD 0.01 billion, respectively. Japan is also expected to benefit from increasing focus on regenerative medicine and advanced therapy adoption.
Latin America and Middle East & Africa
Latin America recorded an estimated value of USD 0.03 billion in 2025, while the GCC market within the Middle East & Africa also reached approximately USD 0.03 billion. Rising genetic disorders and increasing demand for advanced treatment approaches are supporting market development in these regions.
Competitive Landscape
Competition is centered on developing innovative therapies, strengthening R&D capabilities, forming strategic collaborations, expanding manufacturing capacity, and increasing geographical presence. Leading companies are also investing in novel delivery technologies and partnerships with pharmaceutical, academic, and research organizations.
Recent developments, including new AAV vector technologies, manufacturing investments, and strategic funding, demonstrate the industry’s focus on improving treatment delivery, scalability, and market access.
Future Outlook
The gene therapy market is expected to experience strong growth through 2034, supported by increasing demand for treatments targeting genetic disorders, technological advances, and expanding research pipelines. Improvements in gene delivery systems could create additional opportunities by addressing limitations related to delivery efficiency, immune response, payload capacity, and manufacturing scalability.
At the same time, reducing treatment costs and demonstrating long-term clinical durability will remain important for broader adoption. Continued regulatory support, investment, and technological innovation are expected to shape the industry’s future development.
Get a free sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/gene-therapy-market-100243
Conclusion
The global gene therapy market is entering a period of rapid expansion as healthcare providers and biotechnology companies increasingly focus on treatments that address diseases at their genetic source. With the market projected to reach USD 20.68 billion by 2034, the sector is positioned for substantial growth. Rising genetic disease prevalence, expanding R&D activities, advanced gene delivery systems, and improving manufacturing capabilities will remain important growth factors. However, high treatment costs and the need to establish long-term clinical effectiveness continue to present challenges.
Latest 5 Trending FAQs
1. How much is the global gene therapy market worth?
The global gene therapy market was valued at USD 3.57 billion in 2025 and is projected to reach USD 20.68 billion by 2034.
2. What is the projected CAGR of the gene therapy market?
The market is expected to grow at a CAGR of 21.97% from 2026 to 2034.
3. Which region dominates the gene therapy market?
North America dominated the global gene therapy market with a 65.83% share in 2025, supported by strong R&D, healthcare infrastructure, FDA approvals, and funding.
4. Which segment led the gene therapy market by product in 2025?
Zolgensma was the leading product segment in 2025, with an estimated market value of USD 1.23 billion, supported by its durability and application in spinal muscular atrophy treatment.
5. What are the key factors driving the gene therapy market?
The major growth factors include the rising prevalence of genetic disorders, advancements in gene therapy technologies, increasing R&D activities, funding opportunities, product launches, and regulatory approvals.
What’s Driving Japan’s Market? Discover the Latest Gene Therapy Market Insights